JNJ-70218902

JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM) . JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) [1].

Product Specifications

UNSPSC

12352203

Target

CD3; Transmembrane Glycoprotein

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[JNJ-70218902]

References & Citations

[1]Basu S et al. Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models Cancer Research 82.12_Supplement (2022) : LB087-LB087. |[2]Lowenstein C, et al. 1360 Pharmacodynamics of JNJ-70218902, a TMEFF2x CD3 bispecific antibody, in cynomolgus monkey. (2022) .